drugset / Trial / NCT05676697
PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy
Phase 1
Terminated
4 enrolled
Institute of Hematology & Blood Diseases Hospital, China
YL-Pharma · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, single-arm, pilot study. The aim of this study is to evaluate the efficacy and safety of Linperlisib, the PI3K delta inhibitor for autoimmune hemolytic anemia patients who failed the second line therapy.
Timeline
- Start
- 2023-01-13
- Primary completion
- 2024-01-31
- Completion
- 2024-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linperlisib | Small molecule | — | — |